cd4-igg
Recombinant proteinexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000647)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Envelope glycoprotein gp160INHIBITOR
Q993A8 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cd4-igg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000642 | Phase 1 | Nov 2, 1999 | Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000647 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000663 | Phase 1 | Nov 2, 1999 | Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000675 | Phase 1 | Nov 2, 1999 | Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000976 | Phase 1 | Nov 2, 1999 | Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002250 | Phase 1 | Nov 2, 1999 | Genentech |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 5 | 1 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 5 | 2 | 1999 |
2 organizations
Page 1 / 1